Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

Related Articles by Review for PubMed (Select 23546032)

2.

Cost-effectiveness of ticagrelor in acute coronary syndromes.

Henriksson M, Janzon M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):9-18. doi: 10.1586/erp.12.89. Review.

PMID:
23402441
3.

Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2006;24(7):709-26. Review.

PMID:
16802846
4.

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.

Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Review.

5.

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.

PMID:
22104457
6.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

7.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.

8.

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.

Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N.

Health Technol Assess. 2009 Jun;13(31):iii-iv, ix-xi, 1-77. doi: 10.3310/hta13310. Review.

9.

Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.

Berger JS.

Am J Cardiol. 2013 Sep 1;112(5):737-45. doi: 10.1016/j.amjcard.2013.04.055. Epub 2013 Jun 7. Review.

PMID:
23751937
10.

Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.

Cheng JW.

Clin Ther. 2012 Jun;34(6):1209-20. doi: 10.1016/j.clinthera.2012.04.005. Epub 2012 Apr 21. Review.

PMID:
22521881
11.
12.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
13.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

14.

Ticagrelor: a review of its use in the management of acute coronary syndromes.

Deeks ED.

Drugs. 2011 May 7;71(7):909-33. doi: 10.2165/11206850-000000000-00000. Review.

PMID:
21568367
15.

Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.

Clemmensen P, Dridi NP, Holmvang L.

Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Review.

PMID:
23380983
16.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
17.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

18.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Kom├│csi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
19.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

20.

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.

Husted S, van Giezen JJ.

Cardiovasc Ther. 2009 Winter;27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk